Pricing for oral GLP-1 medications in 2026 is more competitive than it's ever been — but it's also more confusing. Manufacturer savings programs, introductory offers, dose-dependent pricing, and expiration dates on promotions create a landscape where the number you see on an advertisement may have little relationship to what you'll actually pay over the course of treatment.
This guide cuts through the marketing to show what each oral GLP-1 medication actually costs at every dose level, with and without savings programs, as of May 2026.
The Three Oral GLP-1 Options
Three oral GLP-1 medications are currently available in the United States, though they serve different approved indications:
Foundayo (orforglipron) — Eli Lilly. FDA-approved April 2026 for chronic weight management. Once daily, no food/water restrictions.
Wegovy pill (oral semaglutide) — Novo Nordisk. FDA-approved December 2025 for chronic weight management. Once daily, requires empty stomach and 30-minute fast.
Rybelsus (oral semaglutide) — Novo Nordisk. FDA-approved for type 2 diabetes (not weight management). Same active ingredient as Wegovy pill but at lower doses. Sometimes prescribed off-label for weight loss, though the approved weight management doses are only available in the Wegovy pill formulation.
Foundayo Pricing
Foundayo (orforglipron) — Eli Lilly
Savings card valid through December 31, 2026. Must refill within 45 days of previous fill to maintain eligibility for $299 pricing on maintenance doses. Not available to government insurance recipients.
Wegovy Pill Pricing
Wegovy Pill (oral semaglutide) — Novo Nordisk
Novo Nordisk introductory pricing valid through August 31, 2026 (subject to change). After introductory period, 4 mg dose rises to $199/month. Not available to government insurance recipients.
Rybelsus Pricing
Rybelsus (oral semaglutide) — Novo Nordisk
Rybelsus may be covered by insurance for type 2 diabetes at favorable copays. For weight loss specifically, insurance coverage is less likely. Maximum approved dose (14 mg) is lower than the Wegovy pill's weight management dose (25 mg).
What These Numbers Don't Show You
The pricing cards above reflect the best-case scenario using manufacturer savings programs. Here's what can change the math:
Savings programs expire. Both Lilly's and Novo Nordisk's current programs have end dates (December 31, 2026 and August 31, 2026, respectively). After those dates, pricing may change — potentially significantly. Companies may extend or modify their programs, but there's no guarantee.
Dose escalation changes your cost. You won't stay at the starting dose. Most patients reach maintenance doses within 4–5 months. The $149/month price is temporary — the $299/month price is what you'll pay for the majority of your treatment.
Telehealth platform fees are additional. If you're accessing these medications through a telehealth platform, you may have consultation fees ($0–$99 per visit), monthly subscription fees ($25–$50/month), and shipping costs on top of the medication price.
Insurance changes everything — in either direction. If your commercial insurance covers GLP-1 medications for weight loss, your out-of-pocket cost may drop to a copay of $25–$100/month. If you don't have coverage and don't qualify for savings programs (government insurance recipients, for example), the list price can exceed $1,000/month.
12-Month Cost Comparison
Here's what a realistic 12-month treatment course costs for a self-pay patient using manufacturer savings programs, assuming standard titration to the maintenance dose:
12-Month Total Comparison (Self-Pay with Savings Programs)
Foundayo and Wegovy pill costs assume manufacturer savings programs remain available for the full 12 months. Rybelsus self-pay cost is dramatically higher because it does not have a comparable weight-management savings program; patients with diabetes-indication insurance coverage will pay much less.
When Cost Shouldn't Be the Deciding Factor
For patients comparing Foundayo and the Wegovy pill specifically, the pricing is close enough that it shouldn't be the primary decision driver. The difference between $3,200 and $3,400 over 12 months is trivial compared to the differences in convenience, weight loss efficacy, and cardiovascular data that distinguish these medications.
Cost becomes a more significant factor in other scenarios: choosing between oral and injectable options (injectables can be cheaper with insurance coverage or more expensive without it), choosing between FDA-approved and compounded options (compounded medications may be cheaper at higher doses), and determining whether to pursue insurance coverage or self-pay (prior authorization for insurance coverage takes effort but can reduce costs substantially).
How to Minimize Your Cost
Check insurance first. Even if you expect your plan won't cover it, verify. Coverage is expanding rapidly, and a 5-minute call to your insurer could save you thousands. Ask specifically about the medication you want — coverage decisions are drug-specific.
Use manufacturer savings programs. These are the single most effective way to reduce self-pay costs. Both Lilly and Novo Nordisk offer savings cards through their websites and through participating telehealth platforms and pharmacies.
Ask about alternative doses. If you're responding well at a lower dose, you may not need the maximum dose. A conversation with your provider about whether a lower (and cheaper) maintenance dose is appropriate for you is reasonable and clinically responsible.
Compare total cost, not starting cost. The $149/month headline is the titration price. The $299/month maintenance price is what you'll pay for most of your treatment. Use the maintenance price in your budgeting.
Watch for program changes. Manufacturer savings programs change. Set a reminder to check for updates before your current program's expiration date. New promotions, extended offers, or price changes may affect your costs.